

**LIST OF INFORMATION DISCLOSED BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO. <b>05213-0113</b>	SERIAL NO. <b>08/468,792</b>	FILING DATE <b>June 6, 1995</b>
APPLICANT <b>Robert D'Amato</b>		GROUP <b>1205</b>

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	AA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
W	AA	2,830,991	4/15/58	Keller et al.	546	200	
W	AB	3,560,495	2/2/71	Frankus et al.	544	130	
W	AC	3,563,986	2/16/71	Frankus et al.	544	130	
W	AD	3,625,946	12/7/71	Koch et al.	546	200	
W	AE	3,705,162	12/5/72	Graudums et al.	546	187	
CP	AF	4,552,888	11/12/85	Koppel et al.	514	474	
CP	AG	4,994,443	2/19/91	Folkman et al.	514	56	
CP	AH	5,001,116	3/19/91	Folkman et al.	514	56	
CP	AI	5,021,404	6/4/91	Folkman et al.	514	26	
W	AJ	5,134,127	7/28/92	Stella et al.	514	58	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION	
						YES	NO
CP	AK	58-131978	8/6/83	Japan			
CP	AL	63-119500	5/24/88	Japan			
CP	AM	0325199	7/26/89	EPO			
CP	AN	0357061	3/7/90	EPO			
CP	AO	WO 92/14455	9/3/92	PCT			

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

CP	AP	Fabro, S. et al., "Teratogenic Activity of Thalidomide and Related Compounds," <u>Life Sciences</u> , 3:987-992 (1964).
W	AR	Shealy et al., "D- and L-Thalidomide," <u>Chem. and Indus.</u> , pp. 1030-1031 (June 12, 1965).
W	AS	Folkman, "Tumor Angiogenesis: Therapeutic Implications," <u>The New England Journal of Medicine</u> , 285(21):1182-1186 (11/18/71).
W	AT	Jonsson, N. Ake, et al., "Chemical Structure and Teratogenic Properties," <u>Acta Pharm. Succica</u> , 9:521-542 (1972)

EXAMINER <i>Cond Nall</i>	DATE CONSIDERED 10/4/96
------------------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered 6/4/92

FORM PTO-1449, Adapted

**LIST OF INFORMATION DISCLOSED BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO. <b>05213-0113</b>	SERIAL NO. <b>08/468,792</b>	FILING DATE <b>June 6, 1995</b>
APPLICANT <b>ROBERT D'AMATO</b>		GROUP

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.	
<i>✓</i>	BL	1,182,709	3/4/70	Great Britain	Kwizda		
<i>✓</i>	BM	WO 92/18496	10/29/92	International	Grunenthal GMBH		X
	BN						
	BO						

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

<i>CP</i>	BP	Jonsson, N. Ake, et al., "Chemical Structure and Teratogenic Properties," <u>Acta Pharm. Succica</u> , 9:431-446 (1972).
<i>CP</i>	BR	Jonsson, N. Ake, et al., "Chemical Structure and Teratogenic Properties," <u>Acta Pharm. Succica</u> , 9:543-562 (1972).
<i>CP</i>	BS	Eriksson, Sven O., "Synthesis and Alkaline Hydrolysis of some N-substituted Phthalimides," <u>Acta Pharm. Succica</u> , 10:63-74 (1973)
<i>WD</i>	BT	Gimbrone et al., "Tumor Growth and Neovascularization: An Experimental Model Using the Rabbit Cornea," <u>J. Nat'l Cancer Institute</u> , 52(2):413-419 (1974).

EXAMINER <i>Carl Dole</i>	DATE CONSIDERED <i>10/4/96</i>
------------------------------	-----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered 6/4/92

FORM PTO-1449, Adapted

**LIST OF INFORMATION DISCLOSED BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.	FILING DATE
05213-0111	08/168,817	December 15, 1993
APPLICANT		GROUP
Robert D'Amato		1209

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

	CA	Fickentscher, K., "Stereochemical Properties and Teratogenic Activity of Some Tetrahydrophthalimides," <u>Mol. Pharmacology</u> , 13:133-141 (1977).
W	CB	Knighton et al., "Avascular And Vascular Phases Of Tumor Growth In The Chick Embryo," <u>Br. J. Cancer</u> , 35:347-356 (1977).
W	CC	Blaschke, "Chromatographic Separation of Racemic Thalidomide and Teratogenic Activity of its Enantiomers (Chromatographische Racemattrennung von Thalidomid und teratogene Wirkung der Enantiomere)," <u>Drug Research</u> , 29 (II/10): 1640-1642 (1979). (English lang. summary on first page)
W	CD	Muthukkaruppan et al., "Angiogenesis in the Mouse Cornea," <u>Science</u> , 205:1416-1418 (9/28/79).
W	CE	Waters, et al., "Treatment of Ulcerative Colitis with Thalidomide," <u>British Medical Journal</u> , p. 792 (Mar. 24, 1979).
W	CF	Flohe et al., "Studies on the Hypothetical Relationship of Thalidomide-induced Embryopathy and Collagen Biosynthesis," <u>Arzneimittelforschung (GERMANY, WEST)</u> , 31(2):315-20 (1981).
W	CG	Helm, <u>Drug Research</u> , 31 (I/6): 941-949 (1981).
W	CH	Taylor et al., <u>Nature</u> , 297: p. 307 (1982).
W	CI	Belaube et al., "Should Thalidomide be Rehabilitated?," <u>Sem. Hôp. Paris</u> , 59(45):3101-3104 (Dec. 8, 1983).
W	CJ	Folkman et al., <u>Science</u> , 221: p. 719 (1983).
W	CK	Hendler, Sheldon S. et al., "Thalidomide for Autoimmune Disease," <u>Medical Hypotheses</u> , 10:437-443 (1983).
W	CL	Crum et al., <u>Science</u> , 230: 1375 et seq. (1985).
W	CM	Koch, H.P. et al., "Thalidomide and Cogeners as Anti-inflammatory Agents," <u>Progress in Medicinal Chemistry</u> , 22:166-242 (1985).
W	CN	Sidky et al., <u>Cancer Research</u> , 47: pp. 5155-5161 (1987).
W	CO	Srivastava et al., "The Prognostic Significance of Tumor Vascularity in Intermediate-Thickness Skin Melanoma," <u>Am. J. Pathol.</u> , 133:419-423 (1988). (abstract from MEDLINE: Accession no. 06745734)
W	CP	Chen et al., "Plasma Pharmacokinetics and Urinary Excretion of Thalidomide After Oral Dosing in Healthy Male Volunteers," <u>Drug Metabolism and Disposition</u> , 17(4):402-405 (1989).
W	CQ	White et al., <u>New England J. Med.</u> , 320: pp. 1197-1200 (1989).
W	CR	Folkman et al., "Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia," <u>Nature</u> , 339:58-61 (5/4/89).
W	CS	"Thalidomide," <u>The Merck Index</u> , Eleventh Edition, Budavari et al., eds., Merck & Co., New Jersey, p. 9182 (1989).
W	CT	Eger, K. et al., "Synthesis, Central Nervous System Activity and Teratogenicity of a Homothalidomide," <u>Arzneim.-Forsch/Drug Res.</u> 40 (II. Nr. 10):1073-1075 (1990).
W	CU	Ingber et al., "Synthetic Analogs Of Fumagillin That Inhibit Angiogenesis And Suppress Tumour Growth," <u>Nature</u> , 348:555-557 (12/6/90).
W	CV	Brem et al., <u>Neurosurg.</u> , 74: 441-446 (1991).

EXAMINER	DATE CONSIDERED
Gustafson	10/4/96

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

all considered 6/4/97

**LIST OF INFORMATION DISCLOSED BY APPLICANT***(Use several sheets if necessary)*

ATTY. DOCKET NO.		SERIAL NO.	FILING DATE
05213-0111		08/168,817	December 15, 1993
APPLICANT			GROUP
Robert D'Amato			1209
<b>OTHER REFERENCES</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
CP	DA	Matsuyama, Toshifumi, "Cytokines and HIV infection: is AIDS a Tumor Necrosis Factor Disease?," <u>AIDS</u> , 5(12):1405-1417 (1991).	
W	DB	Weidner et al., "Tumor Angiogenesis and Metastasis - Correlation in Invasive Breast Carcinoma," <u>N.E.J. Med.</u> , 324(1):1-8 (1991).	
W	DC	Colville-Nash et al., "Angiogenesis and Rheumoid Arthritis: Pathogenic and Therapeutic Implications," <u>Ann. Rheum. Dis.</u> , 51:919-925 (1992).	
W	DD	Folkman and Shing, "Angiogenesis," <u>J. Biol. Chem.</u> , 267(16):10931-10934 (1992).	
W	DE	Schweigerer and Fotsis, "Angiogenesis and angiogenesis inhibitors in paediatric diseases," <u>Eur. J. Pediatr.</u> 151:472-476 (1992).	
W	DF	Torry and Rongish, Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis," <u>Am. J. Reprod. Immunol.</u> , 27:171-179 (1992).	
W	DG	Vogelsang et al., "Thalidomide for the Treatment of Chronic Graft-Versus-Host Disease," <u>New England Journal of Medicine</u> , 326:1055-1058 (1992).	
P	DH	Weidner et al., "Angiogenesis in Prostate Carcinoma," <u>Am. J. Path.</u> , 143(2):401-409 (1993).	
W	DI	D'Amato et al., "Thalidomide is an Inhibitor of Angiogenesis," <u>PNAS USA</u> , 91:4082-4085 (1994).	
W	DJ	Oikawa et al., "Eponemycin, A Novel Antibiotic, is a Highly Powerful Angiogenesis Inhibitor," <u>Biochem. Biophys. Res. Comm.</u> , 181(3):1070-1076 (Dec. 31, 1991).	
W	DK	Otsuka et al., "A New Potent Angiogenesis Inhibitor, FR-118487," <u>J. Microb. Biotech.</u> , 1(3):163-168 (1991).	
	DL		
	DM		
	DN		
	DO		
	DP		
	DQ		
	DR		
	DS		
	DT		
	DU		
	DV		
EXAMINER <i>Garth R. Ball</i>			DATE CONSIDERED 10/4/94

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.